Novel mitophagy inducer TJ0113 alleviates pulmonary inflammation during acute lung injury
Frontiers in Pharmacology · 09.07.2025 · 16
DOI: 10.3389/fphar.2025.1590458 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 09.07.2025. Verfasst von Zhengyuan Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zheji…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Acute lung injury (ALI) is a severe respiratory disease with limited effective therapeutic options. Recent studies have highlighted mitochondrial damage as a crucial factor in the progression of ALI. Mitophagy, which facilitates the removal of damaged mitochondria, has been shown to reduce inflammation. Our collaborators constructed a small molecule mitophagy inducer, TJ0113. TJ0113 has been approved to initiate a Phase I clinical trial for Alport syndrome and a Phase II trial for Parkinson's disease in China. Therefore, we explored the potential of TJ0113 as a novel therapeutic for ALI.
Methods
The mitophagy-inducing potential of TJ0113 was assessed in HEK293T cells. The anti-inflammatory effects of TJ0113 were further evaluated in vivo using a mouse model of lipopolysaccharide (LPS)-induced ALI and in vitro using LPS-stimulated bone-marrow-derived macrophages (BMDMs).
Results
TJ0113 selectively induced mitophagy in damaged mitochondria. Furthermore, the PINK1–Parkin pathway was identified as a specific mitophagy pathway induced by TJ0113. In LPS-induced ALI mouse model, intraperitoneal injection of TJ0113 significantly reduced lung inflammation and mortality. In vitro , TJ0113 significantly inhibited the expression of LPS-induced inflammatory cytokines in BMDMs. Finally, we found that TJ0113 inhibited LPS-induced inflammation by inducing mitophagy and inhibiting nuclear factor κB (NF-κB) and inflammasome activation.
Conclusion
TJ0113 alleviates LPS-induced inflammation by inducing mitophagy and inhibiting NF-κB and inflammasome activation. Its selective action on damaged mitochondria suggests minimal side effects, positioning TJ0113 as a promising therapeutic candidate for ALI.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Key Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Zitieren
APA
Liu, Z., Fang, D., Chen, K., Dong, L., Huang, H., & Chen, Z. (2025). Novel mitophagy inducer TJ0113 alleviates pulmonary inflammation during acute lung injury. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1590458
Vancouver
Liu Z, Fang D, Chen K, Dong L, Huang H, Chen Z. Novel mitophagy inducer TJ0113 alleviates pulmonary inflammation during acute lung injury. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1590458
BibTeX
@article{Liu2025,
author = {Liu, Zhengyuan and Fang, Danruo and Chen, Kaijun and Dong, Lingling and Huang, Huaqiong and Chen, Zhihua},
title = {Novel mitophagy inducer TJ0113 alleviates pulmonary inflammation during acute lung injury},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1590458}
}
EUVIMED